We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

164 hedge funds and large institutions have $6.54B invested in Ascendis Pharma A/S in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 65 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

413% more call options, than puts

Call options by funds: $117M | Put options by funds: $22.8M

8.86% less ownership

Funds ownership: 115.61% → 106.75% (-8.9%)

11% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 65

12% less funds holding

Funds holding: 187 → 164 (-23)

19% less capital invested

Capital invested by funds: $8.05B → $6.54B (-$1.51B)

35% less funds holding in top 10

Funds holding in top 10: 20 → 13 (-7)

57% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 37

Holders
164
Holders Change
-23
Holders Change %
-12.3%
% of All Funds
2.61%
Holding in Top 10
13
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-35%
% of All Funds
0.21%
New
16
Increased
58
Reduced
65
Closed
37
Calls
$117M
Puts
$22.8M
Net Calls
+$94.2M
Net Calls Change
+$7.85M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$73.8M
2
Capital International Investors
Capital International Investors
California
+$48.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$45.3M
4
ACA
Avoro Capital Advisors
New York
+$25.7M
5
WP
Woodline Partners
California
+$24M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$605M
2
DTC
Deep Track Capital
Connecticut
-$85.5M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$38.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$16M
5
Citadel Advisors
Citadel Advisors
Florida
-$15.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
176
Cubist Systematic Strategies
Connecticut
– -$1.17M -9,603 Closed
Millennium Management
177
Millennium Management
New York
– -$919K -7,524 Closed
Susquehanna International Group
178
Susquehanna International Group
Pennsylvania
– -$810K -7,081 Closed
BCM
179
Bayesian Capital Management
New York
– -$794K -6,500 Closed
EGM
180
Engineers Gate Manager
New York
– -$656K -5,368 Closed
PFO
181
Pathstone Family Office
New Jersey
– -$523K -4,484 Closed
First Trust Advisors
182
First Trust Advisors
Illinois
– -$440K -3,602 Closed
IAIM
183
Industrial Alliance Investment Management
Quebec, Canada
– -$419K -3,428 Closed
LCM
184
Legato Capital Management
California
– -$330K -2,701 Closed
DCM
185
Dupont Capital Management
Delaware
– -$284K -2,324 Closed
HA
186
HC Advisors
Georgia
– -$253K -2,075 Closed
TI
187
Trexquant Investment
Connecticut
– -$250K -2,050 Closed
SM
188
SG3 Management
Puerto Rico
– -$244K -2,000 Closed
YIH
189
Y-Intercept (HK)
Hong Kong
– -$215K -1,764 Closed
LPL Financial
190
LPL Financial
California
– -$212K -1,736 Closed
Simplex Trading
191
Simplex Trading
Illinois
– -$185K -1,617 Closed
Group One Trading
192
Group One Trading
Illinois
– -$141K -1,235 Closed
TWA
193
TCI Wealth Advisors
Arizona
– -$8.18K -67 Closed
CAS
194
Coppell Advisory Solutions
Texas
– -$90 -50 Closed
CASC
195
Coppell Advisory Solutions Corp
Texas
– -$90 -50 Closed
ZB
196
Zions Bancorporation
Utah
– -$4.76K -39 Closed
Rockefeller Capital Management
197
Rockefeller Capital Management
New York
– -$1K -24 Closed
MSCM
198
McElhenny Sheffield Capital Management
Texas
– -$1.59K -13 Closed
BTI
199
Blue Trust Inc
Georgia
– -$1K -6 Closed
MCC
200
Money Concepts Capital
Florida
– -$122 -1 Closed
4 5 6 7
8

ASND Hedge Fund Activity: Q1 2023 in Review

164 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2023, worth a combined $6.54B — down 19% from $8.05B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ASND and 16 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 58 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $73.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $605M sold.

  • 164 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2023, down from 187 in Q4 2022.
  • Funds reported $6.54B of Ascendis Pharma A/S stock for Q1 2023, down 19% quarter-over-quarter.
  • 16 funds opened new Ascendis Pharma A/S positions in Q1 2023 and 37 closed out, a net change of -21 holders.
  • The largest Ascendis Pharma A/S buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $73.8M added.
  • The largest Ascendis Pharma A/S seller in Q1 2023 was Baker Bros. Advisors, an estimated $605M sold.

Based on aggregated 13F filings for Q1 2023.